These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management. Westfall E; Jeske R; Bader AR Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890 [TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research. Gottlieb A; Mosthael W; Sowa JP; Canbay A Digestion; 2019; 100(2):79-85. PubMed ID: 30537758 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. Popov VB; Lim JK J Clin Transl Hepatol; 2015 Sep; 3(3):230-8. PubMed ID: 26623270 [TBL] [Abstract][Full Text] [Related]
14. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. Khan FZ; Perumpail RB; Wong RJ; Ahmed A World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027 [TBL] [Abstract][Full Text] [Related]
15. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845 [TBL] [Abstract][Full Text] [Related]
16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]
17. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management]. Kim SK; Kim KI; Kim SR Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630 [TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
19. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. Yoon IC; Eun JR Yeungnam Univ J Med; 2019 May; 36(2):67-77. PubMed ID: 31620616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]